Verition Fund Management LLC Trims Position in Krystal Biotech, Inc. (NASDAQ:KRYS)

Verition Fund Management LLC lessened its position in shares of Krystal Biotech, Inc. (NASDAQ:KRYSGet Rating) by 59.1% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 31,166 shares of the company’s stock after selling 44,948 shares during the quarter. Verition Fund Management LLC’s holdings in Krystal Biotech were worth $2,074,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the company. Great West Life Assurance Co. Can grew its holdings in Krystal Biotech by 51.9% during the first quarter. Great West Life Assurance Co. Can now owns 1,013 shares of the company’s stock valued at $72,000 after purchasing an additional 346 shares during the period. Lazard Asset Management LLC grew its holdings in Krystal Biotech by 39.2% during the first quarter. Lazard Asset Management LLC now owns 1,771 shares of the company’s stock valued at $117,000 after purchasing an additional 499 shares during the period. E Fund Management Co. Ltd. bought a new stake in Krystal Biotech during the first quarter valued at about $200,000. Commonwealth Equity Services LLC bought a new position in shares of Krystal Biotech in the first quarter worth about $234,000. Finally, Teacher Retirement System of Texas bought a new position in shares of Krystal Biotech in the first quarter worth about $238,000. Hedge funds and other institutional investors own 81.14% of the company’s stock.

Krystal Biotech Trading Down 3.9 %

Shares of Krystal Biotech stock opened at $68.52 on Monday. The stock has a 50 day moving average of $72.82 and a 200 day moving average of $66.74. Krystal Biotech, Inc. has a 12 month low of $38.86 and a 12 month high of $102.99. The firm has a market cap of $1.76 billion, a PE ratio of -14.49 and a beta of 0.89.

Krystal Biotech (NASDAQ:KRYSGet Rating) last issued its quarterly earnings data on Monday, August 8th. The company reported ($1.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.08) by ($0.02). As a group, equities research analysts forecast that Krystal Biotech, Inc. will post -5.36 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the company. Chardan Capital dropped their price objective on Krystal Biotech from $137.00 to $130.00 and set a “buy” rating for the company in a research note on Tuesday, August 9th. The Goldman Sachs Group lowered Krystal Biotech from a “buy” rating to a “neutral” rating and set a $74.00 price objective for the company. in a research note on Wednesday, August 24th.

About Krystal Biotech

(Get Rating)

Krystal Biotech, Inc, a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa.

Further Reading

Want to see what other hedge funds are holding KRYS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Krystal Biotech, Inc. (NASDAQ:KRYSGet Rating).

Institutional Ownership by Quarter for Krystal Biotech (NASDAQ:KRYS)

Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.